+

WO2018155612A1 - Composition pour la prévention et/ou le traitement d'une infection associée à la salmonelle comprenant une souche de bacillus amyloliquefaciens et/ou un produit traité de ladite souche - Google Patents

Composition pour la prévention et/ou le traitement d'une infection associée à la salmonelle comprenant une souche de bacillus amyloliquefaciens et/ou un produit traité de ladite souche Download PDF

Info

Publication number
WO2018155612A1
WO2018155612A1 PCT/JP2018/006627 JP2018006627W WO2018155612A1 WO 2018155612 A1 WO2018155612 A1 WO 2018155612A1 JP 2018006627 W JP2018006627 W JP 2018006627W WO 2018155612 A1 WO2018155612 A1 WO 2018155612A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
salmonella
bacillus amyloliquefaciens
present
feed
Prior art date
Application number
PCT/JP2018/006627
Other languages
English (en)
Japanese (ja)
Inventor
元一郎 瀬尾
佐藤　直樹
和夫 福井
太樹夫 稲富
智英 増田
Original Assignee
東亜薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東亜薬品工業株式会社 filed Critical 東亜薬品工業株式会社
Publication of WO2018155612A1 publication Critical patent/WO2018155612A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Definitions

  • the present invention uses a composition for preventing, controlling, suppressing, reducing, alleviating, and / or treating infectious diseases related to Salmonella containing a Bacillus amyloliquefaciens strain and / or a processed product of the strain, and the composition.
  • the present invention relates to a method for treating an infection related to Salmonella.
  • Patent Document 1 discloses a “Bacillus amyloliquefaciens strain with deposit number NITE ABP-01844”. However, Patent Document 1 does not disclose or suggest that the Bacillus amyloliquefaciens strain is effective for infectious diseases related to Salmonella.
  • Patent Document 2 discloses “an intestinal Salmonella bacterium reducing agent for the addition of avian feed, which contains live cells of Bacillus subtilis C-3102 (Mikokenjoyo No. 1096) as an active ingredient”. ing. However, it does not disclose or suggest the Bacillus amyloliquefaciens strain having the deposit number NITE ABP-01844, which is a strain according to the present invention.
  • An object of the present invention is to provide a composition effective for infectious diseases related to Salmonella and a method for treating infectious diseases related to Salmonella.
  • the Bacillus amyloliquefaciens strain has an effect on Salmonella typhimurium, which is a causative agent of Salmonella infectious diseases.
  • the present invention is as follows.
  • a composition for preventing, controlling, suppressing, reducing, alleviating, and / or treating infectious diseases related to Salmonella containing a Bacillus amyloliquefaciens strain and / or a processed product of the strain 2. 2. The composition according to item 1, wherein the infectious disease is an infectious disease in livestock. 3. 3. The composition according to item 1 or 2, wherein the Salmonella is Salmonella typhimurium. 4). 3. The composition according to item 1 or 2, wherein the Salmonella is Salmonella enteritidis. 5). 5. The composition according to any one of items 1 to 4, wherein the Bacillus amyloliquefaciens strain is a strain having the deposit number NITE ABP-01844. 6).
  • a veterinary drug, feed, feed additive, or drinking water comprising the composition according to any one of 1 to 5 above. 7). Salmonella characterized by administering the veterinary drug, feed, feed additive or drinking water according to item 6 and / or the composition according to any one of items 1 to 5 to an animal other than a human. A method of rearing an animal while preventing, controlling, suppressing, reducing, alleviating, and / or treating an infectious disease. 8). A method for breeding livestock while preventing, controlling, suppressing, reducing, alleviating, and / or treating an infection related to Salmonella, comprising a step of administering a Bacillus amyloliquefaciens strain and / or a processed product of the strain to an animal. 9.
  • a method for preventing, controlling, suppressing, reducing, alleviating, and / or treating an infection related to Salmonella comprising a step of administering a Bacillus amyloliquefaciens strain and / or a processed product of the strain to an animal. 10. 10. The method according to item 8 or 9, wherein the Bacillus amyloliquefaciens strain is a strain having the deposit number NITE ABP-01844. 11. A Salmonella typhimurium and / or Salmonella enteritidis control agent comprising a Bacillus amyloliquefaciens strain and / or a processed product of the strain. 12 12.
  • Bacillus amyloliquefaciens strain is a strain having the deposit number NITE ABP-01844.
  • Salmonella typhimurium comprising a step of adding a Bacillus amyloliquefaciens strain and / or a processed product thereof to a place where Salmonella typhimurium and / or Salmonella enteritidis are bred or bred, and / Or Salmonella Enteritidis extermination method.
  • 14 14. The method according to item 13 above, wherein the Bacillus amyloliquefaciens strain is a strain having the deposit number NITE ABP-01844.
  • composition, breeding method or treatment method of the present invention had at least one of the following effects.
  • Immunostimulatory effect in chicken serum lysozyme concentration increasing effect, macrophage phagocytosis increasing effect, macrophage chemotaxis increasing effect, and small intestine total IgA concentration increasing effect).
  • the comparison result of the organic acid production ability of the strain based on this invention and a well-known strain The measurement result of Salmonella typhimurium microbe count of Example 2.
  • FIG. The calculation result of the detection rate of Salmonella typhimurium of Example 2.
  • FIG. The measurement result of the Salmonella typhimurium microbe count of the infected individual
  • FIG. The calculation result of Salmonella typhimurium detection rate of the living individual of Example 3.
  • the composition for preventing, controlling, suppressing, reducing, alleviating and / or treating infectious diseases related to Salmonella of the present invention is at least a Bacillus amyloliquefaciens strain. And / or a processed product of the strain.
  • at least a Bacillus amyloliquefaciens strain and / or a processed product of the strain is preferably used for animals (particularly livestock). Is administered orally or with drinking water.
  • Bacillus amyloliquefaciens strain Bacillus amyloliquefaciens according to the present invention (Bacillus amyloliquefaciens, Bacillus amyloliquefaciens) strains, can utilize known strains, particularly preferred strains, deposited as accession number NITEABP-01844 Is TOA5001 stock.
  • the mycological properties of the strain (bacteria) according to the present invention are as follows. Gram-positive, Neisseria gonorrhoeae, aerobic, spore-forming ability, motility. It is low in auxotrophy and can grow on various media such as gravy medium, SCD medium, brain heart infusion medium. On the agar plate medium, the periphery is rough and yellowish white. Furthermore, depending on the type of the medium (Brain Heart Infusion Medium), a raised colony having viscosity inside is formed.
  • the strain according to the present invention is not limited to the strain deposited under the deposit number NITE ABP-01844, but belongs to Bacillus amyloliquefaciens, and Salmonella (particularly Salmonella, which is the causative agent of Salmonella infection). As long as it has an effect on Tifumilium and Salmonella enteritidis), it can be used as a strain according to the present invention. That is, the Bacillus amyloliquefaciens strain of the present invention is intended to include not only the deposited strain itself but also mutants and progeny that are strains having the above-mentioned mycological properties.
  • the mutant preparation method can be obtained by conventionally known irradiation and chemical substance treatment such as nitrosoguanidine, ethylmethanesulfonic acid, methylmethanesulfonic acid and the like. Furthermore, the strain according to the present invention is not toxic even if it is administered in vivo (particularly in livestock), as shown in the Examples below.
  • the strain according to the present invention is obtained by inoculating a nutrient medium containing a carbon source and a nitrogen source and, if necessary, inorganic salts, followed by culturing under aerobic conditions (for example, shaking culture, aeration and agitation culture), Can be obtained.
  • aerobic conditions for example, shaking culture, aeration and agitation culture
  • the culture solution it is effective against the causative bacteria of the infectious disease (for example, Salmonella typhimurium and Salmonella enteritidis) in the unconcentrated culture solution, and the culture solution after filter sterilization Or they have equivalent activity even after freeze-drying or spray-drying.
  • an infectious disease is caused by using the solid itself or a mixture thereof (for example, a contact or mixture with another solid or a liquid in which the strain-growing solid according to the present invention is immersed). It can have an effect on the causative bacteria.
  • the solid may be any material as long as the strain according to the present invention can grow, and means, for example, a plant body that is a raw material for agar medium, silage, natto and the like, and curd represented by yogurt.
  • Any carbon source may be used as long as the strain according to the present invention can be used.
  • Glucose, sucrose, starches, cellulose mixtures, and other carbohydrates are preferably used.
  • the nitrogen source may be any as long as the strain according to the present invention can be used, but preferably peptone, yeast extract, gravy extract and the like are used.
  • the strain according to the present invention can be grown in a liquid medium or a plate culture inoculated on a commercially available medium, for example, tryptosy medium, brain heart infusion medium, or gravy medium.
  • the culture When culturing in a small amount in liquid culture, shaking culture using a test tube or flask is preferred. When culturing in large quantities, it is preferable to culture with aeration and agitation as in the case of other fermentation products.
  • culture When culture is performed in a large tank, it is preferable to first inoculate and culture the strain according to the present invention in a relatively small amount of medium as a preculture, and then transfer the culture to a large production tank for production culture.
  • the composition of the medium used for the preculture and the medium used for the production culture may be the same, or may be changed if necessary.
  • the culture conditions can be appropriately changed within the range in which the strain according to the present invention grows. Usually, the culture is performed at 15 to 45 ° C., preferably 25 to 37 ° C. under aerobic conditions.
  • the culture time varies depending on the culture conditions and the culture volume, but is usually about 1 day to 1 week.
  • the strain according to the present invention can be recovered from the culture solution obtained by the above culture by centrifugation and / or membrane concentration.
  • the collected bacterial cells may be used as they are, or dried bacterial cells that have been subjected to freeze-drying or spray-drying as necessary.
  • the treated product of the strain according to the present invention is various treatments on the cultured strain (washing, far-dehydration, heating, gamma ray or neutron irradiation, spray drying, freeze drying, sterilization, enzyme, surface activity Agent, grinding, grinding, etc.).
  • composition of the present invention includes at least the strain (including cells) according to the present invention and / or a processed product of the strain, and prevents, controls, suppresses, reduces, alleviates, and / or treats an infection related to Salmonella. And, in some cases, have a control, elimination, and / or cure effect.
  • the infection related to Salmonella of the present invention is not particularly limited as long as it is an infection caused by Salmonella.
  • Salmonella Salmonella Typhimurium , Salmonella Typhimurium , Salmonella Typhi ), Salmonella Agona , Salmonella Saintpaul , Salmonella Heidelberg , Salmonella Choleraesuis , Salmonella Infantis , Salmonella Infantis , Salmonella Infantis (Salmonella Thompson), Salmonella Enteritidis (Salmonella Enteritidis), can be exemplified Salmonella Dublin (Salmonella Dublin) and the like.
  • the target of treatment for infectious diseases is animals including humans (particularly mammals).
  • livestock cattle, pigs, chickens
  • pets more specifically pigs, dogs, cats, fish
  • birds ⁇ chicken Especially, chicks, broilers, egg-laying chickens
  • fattening cattle such as dairy cows, beef cattle, F1 (Holstein and Wagyu crossbreed), milking cows, horses, mice and the like
  • milking cows horses, mice and the like
  • mice and the like can be exemplified, but not particularly limited.
  • any concentration may be used as long as the desired effect can be exerted.
  • the strain according to the present invention is 1 kg. It is preferable to feed the feed added so as to be 10 5 to 10 9 cfu (Colony forming unit).
  • the administration time, administration method, and dose of the composition of the present invention are not particularly limited, but it may be usually added to a commercial feed or mixed diet.
  • the amount of administration (feeding, feeding) when blended with commercial feed or administered with mixed feeding (feeding, feeding) is 0.005% to 10%.
  • the dose of the composition of the present invention is not particularly limited. For example, it is desirable to add 0.005% to 10% to a commercial feed.
  • composition of this invention is as follows, for example.
  • Composition for prevention, control, suppression, reduction, alleviation, and / or treatment of infectious diseases related to Salmonella (2) Feed for animal (particularly livestock), feed additive and breeding water
  • Prevention, control, suppression, reduction and alleviation of infectious diseases related to Salmonella characterized by administering veterinary drugs, feeds, feed additives or drinking water and / or the composition of the present invention to animals other than humans And / or methods of raising animals while being treated are also of interest.
  • the present invention is also directed to a method of combating Salmonella typhimurium and Salmonella enteritidis.
  • the Salmonella typhimurium and / or Salmonella enteritidis control agent of the present invention contains at least a Bacillus amyloliquefaciens strain and / or a processed product of the strain.
  • the pesticide of the present invention relates to Salmonella by adding it to a place where Salmonella typhimurium and / or Salmonella enteritidis are breeding or expected to breed (particularly a breeding facility, aquarium, etc.). It is possible to prevent, suppress, reduce, etc. the occurrence of infectious diseases.
  • the Salmonella typhimurium and / or Salmonella enteritidis extermination method of the present invention comprises at least a Bacillus amyloliquefaciens strain and / or a processed product of the strain as Salmonella typhimurium and / or Salmonella enteritidis. Is added to the place where breeding or breeding (especially breeding facilities, aquariums, etc.).
  • the composition of the present invention widely includes veterinary drugs, foods and drinks, feed additives, feeds (formulated feeds, mixed feeds), and breeding water having the above uses.
  • the composition of the present invention is blended with additives such as starch, potato starch, lactose, soybean protein and the like, excipients, binders, disintegrants, lubricants, stabilizers, suspending agents and the like. These can be formulated into powders, tablets, granules, capsules, ointments, liquids and the like by known methods.
  • the organic acid producing ability of the strain according to the present invention was compared with the known strain organic acid producing ability. Details are as follows.
  • the strain according to the present invention and the known strain, B. subtilis reference strain were cultured under the same culture conditions. Specifically, each strain was inoculated into a separate brain heart infusion liquid medium (manufactured by BBL) and cultured with shaking at 37 ° C. for 24 hours. After the culture, the liquid phase and the solid phase cells were separated from the culture solution by cooling centrifugation (10000 ⁇ g, 10 minutes).
  • the obtained liquid phase part was sterilized and filtered through a 0.45 ⁇ m membrane filter.
  • the filtered liquid was used as a culture supernatant for organic acid measurement by the following HPLC.
  • About 0.2 ml of the culture supernatant of each strain was collected in a 1.5 mL tube, and 50 ⁇ L of 500 mM trans-crotonic acid was added as an internal standard substance. Then, it extracted twice with 0.6 mL of 0.25% ammonia as an extract.
  • To the obtained supernatant 0.3 times the amount of 10% HClO 4 was added to precipitate and remove the protein.
  • the obtained supernatant was filtered through a 0.45 ⁇ m membrane filter to obtain an HPLC sample.
  • HPLC was performed under the following conditions.
  • HPLC system manufactured by Waters Column: Organic Acid Column (7.8 ⁇ 300 mm) and guard column (6.0 ⁇ 50 mm) Column temperature and post-column reaction temperature: 60 ° C Flow rate: 0.8mL / min Mobile phase: 0.08% HClO 4 Reaction phase: 0.2 mM BTB, 5.2 mM NaOH, 15 mM Na 2 HPO 4 Detection wavelength: 445 nm
  • the comparison result of the organic acid production ability computed from the result of HPLC is shown in FIG.
  • the acetic acid producing ability of the strain according to the present invention is at least 2.7 times (48.7 / 4) higher than the acetic acid producing ability of the known Bacillus subtilis reference strain. 17.9). From the above results, the strain according to the present invention has higher organic acid producing ability than known strains. More specifically, since organic acids including acetic acid have antibacterial action, it was confirmed that the strain according to the present invention has higher antibacterial activity than known strains.
  • the day of gavage administration was fed on a commercial feed for adult chickens (SDL No. 4 [manufactured by Nippon Formulad Feed Co., Ltd.)] for all wards, and was reared for 28 days.
  • SDL No. 4 manufactured by Nippon Formulad Feed Co., Ltd.
  • test group 1 feed after culturing for 2 to 3 days under the same culture conditions as in Example 1, the cells recovered by centrifugation were mixed with rice bran oil cake and air-dried to obtain 1 ⁇ 10 8 cfu / g dry powder.
  • the known Bacillus subtilis strain was added to a 2.0 ⁇ 10 5 cfu / g feed.
  • test group 2 feed After culturing for 2 to 3 days under the same culture conditions as in Example 1, the cells recovered by centrifugation were mixed with rice bran oil cake and air-dried to obtain 1 ⁇ 10 8 cfu / g dry powder.
  • the strain of the present invention was added to 2.0 ⁇ 10 5 cfu / g feed.
  • 14th and 28th days after the start of the test 5 birds were sacrificed in each group, the contents of the cecum were collected, and the number of Salmonella typhimurium bacteria (log cfu / g) was measured. Furthermore, the detection rate (%) was calculated from the presence or absence of detection of Salmonella typhimurium in the cecal contents of 5 individuals in each section 3 days, 14 days and 28 days after the start of the test.
  • the measurement result of Salmonella typhimurium bacteria count is shown in FIG. As is clear from FIG. 2, in test group 2, the number of Salmonella typhimurium in the cecum decreased by 28.4% between 3 and 28 days after the start of the test, whereas in test group 1 The number of Salmonella typhimurium in the cecum decreased by 2.2% over 28 days, and the number of Salmonella typhimurium in the cecum increased by 12.3% over 28 days in the control group. The calculation result of the detection rate of Salmonella typhimurium is shown in FIG. As apparent from FIG.
  • the strain of the present invention has an effect of suppressing the growth of Salmonella typhimurium in adult chickens. Moreover, it confirmed that it had the Salmonella typhimurium inhibitory effect superior to the well-known Bacillus subtilis strain
  • test group 1 diet was added a known Bacillus subtilis strain was the same dry powder as in Example 2 so as to be 2.0 ⁇ 10 5 cfu / g forage.
  • strain of the present invention in the form of a dry powder was added in the same manner as in Example 2 so as to be 2.0 ⁇ 10 5 cfu / g feed.
  • FIG. 4 shows the measurement results of the number of cecal Salmonella typhimurium bacteria (log cfu / g) in infected individuals.
  • the number of Salmonella typhimurium bacteria in the chicken chick was 25.7% lower than that in the control group and 8% lower than that in the test group 1. Therefore, it was confirmed that the strain of the present invention has an effect of suppressing the growth of Salmonella typhimurium in the chick chick.
  • FIG. 5 shows the result of the infection status ⁇ detection rate of Salmonella typhimurium (%) ⁇ in the cecum of the chicken] for the lived individual. As is clear from FIG.
  • the strain of the present invention has an effect of preventing Salmonella typhimurium infection in chicken chicks. Moreover, it confirmed that it had the Salmonella typhimurium infection prevention effect superior to the well-known Bacillus subtilis strain
  • the strain of the present invention in the form of a dry powder was added in the same manner as in Example 2 so as to be 2.0 ⁇ 10 5 cfu / g feed.
  • the temperature inside the poultry house was 30 ° C. for 1-7 days of age, 28-25 ° C. for 8-21 days, 24-22 ° C. for 22-35 days, and 20 ° C. after 36 days.
  • immune indices serum lysozyme concentration, macrophage phagocytosis, macrophage chemotaxis, and small intestine total IgA concentration
  • Serum lysozyme concentration was measured using ELISA measurement kit (manufactured by SIGMA-ALDRICH) according to the manufacturer's manual. Macrophage phagocytosis rate and macrophage chemotaxis can be determined by immunological function analysis manual ([online], September 29, 2016, National Livestock Improvement Center Hyogo Farm Special Breeding Subcommittee, [Search February 8, 2017], ⁇ Http://www.nlbc.go.jp/hyogo/tishiki/boueki/boueki/boueki/c21bd718afed5f0d1adee9349fd0b4ffe9b5c9cb.pdf>).
  • the small intestine IgA concentration was measured according to the manufacturer's manual using an ELISA measurement kit (Bethel Laboratories, Inc.).
  • the results of serum lysozyme concentration are shown in FIG. As is clear from FIG. 6, in the test group 2, the serum lysozyme concentration ( ⁇ g / mL) was higher than that in the control group and the test group 1.
  • the result of macrophage phagocytosis is shown in FIG. As is clear from FIG. 7, the macrophage phagocytosis rate (%) in test group 2 was higher than that in control group and test group 1.
  • the results of macrophage chemotaxis are shown in FIG. As is clear from FIG. 8, macrophage chemotaxis (%) was higher in test group 2 than in control group and test group 1.
  • the results of the small intestine total IgA concentration are shown in FIG. As is clear from FIG.
  • the test group feed was added strains of the present invention which was the same dry powder as in Example 2 so as to be 2.0 ⁇ 10 6 cfu / g forage.
  • the feed start date of the feed is day 0 (before feeding), 10 days, 12 days, 14 days, 16 days, 21 days, and 35 days.
  • the detection rate (%) was calculated from the presence or absence of detection of Salmonella enteritidis bacteria in the cecum contents.
  • the calculation result of the detection rate of Salmonella enteritidis is shown in FIG. As is clear from FIG. 11, in the control group, the detection rate was 100% (15/15 birds) at 0 days, 10 days, 12 days, 14 days, and 35 days after the start of salary, In the test area, the detection rate decreased to 33.3% (5/15) on the 35th. From the above, it was confirmed that the strain of the present invention has an effect of inhibiting the growth of Salmonella enteritidis in adult chickens.
  • Example 3 (Salmonella enteritidis infection prevention test in chicks) The procedure was the same as in Example 3 except that Salmonella enteritidis wild strain was forcibly administered orally instead of Salmonella typhimurium wild strain.
  • the strain of the present invention has an effect of suppressing the growth of Salmonella enteritidis in chicken chicks. Moreover, it confirmed that the strain of this invention has the Salmonella enteritidis infection prevention effect of a chicken chick. Furthermore, it was confirmed that it has a better Salmonella enteritidis infection prevention effect than the known Bacillus subtilis strain.
  • compositions, breeding method or treatment method of the present invention had the following effects.
  • Immunostimulatory effect in livestock serum lysozyme concentration increasing effect, macrophage phagocytosis increasing effect, macrophage chemotaxis increasing effect, and small intestine total IgA concentration increasing effect).
  • the present invention can provide a composition for preventing and / or treating infectious diseases related to Salmonella containing a Bacillus amyloliquefaciens strain and / or a processed product of the strain.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Fodder In General (AREA)

Abstract

L'invention concerne une composition efficace pour une infection liée à la salmonelle. On a découvert que la souche de Bacillus amyloliquefaciens est efficace sur Salmonella typhiméthylium, qui est une bactérie responsable d'une infection liée à la salmonelle.
PCT/JP2018/006627 2017-02-24 2018-02-23 Composition pour la prévention et/ou le traitement d'une infection associée à la salmonelle comprenant une souche de bacillus amyloliquefaciens et/ou un produit traité de ladite souche WO2018155612A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017034085 2017-02-24
JP2017-034085 2017-02-24

Publications (1)

Publication Number Publication Date
WO2018155612A1 true WO2018155612A1 (fr) 2018-08-30

Family

ID=63253846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/006627 WO2018155612A1 (fr) 2017-02-24 2018-02-23 Composition pour la prévention et/ou le traitement d'une infection associée à la salmonelle comprenant une souche de bacillus amyloliquefaciens et/ou un produit traité de ladite souche

Country Status (1)

Country Link
WO (1) WO2018155612A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021055474A1 (fr) * 2019-09-16 2021-03-25 Microbiome Labs, Llc Supplémentation probiotique à base de spores chez des poulets et effet sur des charges de salmonelle

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015115790A1 (fr) * 2014-01-28 2015-08-06 씨제이제일제당 (주) Souche de bacillus sp. ayant une productivité en farine de soja fermentée améliorée, et procédé de préparation de farine de soja fermentée l'utilisant
CN105567598A (zh) * 2016-01-15 2016-05-11 西北农林科技大学 一种藏猪源解淀粉芽孢杆菌及其应用
JP2016116466A (ja) * 2014-12-19 2016-06-30 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015115790A1 (fr) * 2014-01-28 2015-08-06 씨제이제일제당 (주) Souche de bacillus sp. ayant une productivité en farine de soja fermentée améliorée, et procédé de préparation de farine de soja fermentée l'utilisant
JP2016116466A (ja) * 2014-12-19 2016-06-30 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
CN105567598A (zh) * 2016-01-15 2016-05-11 西北农林科技大学 一种藏猪源解淀粉芽孢杆菌及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021055474A1 (fr) * 2019-09-16 2021-03-25 Microbiome Labs, Llc Supplémentation probiotique à base de spores chez des poulets et effet sur des charges de salmonelle

Similar Documents

Publication Publication Date Title
JP6106211B2 (ja) 動物の健康を向上するためにバチルス・ズブチリス株を使用する方法
AU721811B2 (en) Animal feed
JP6012111B2 (ja) 動物用飼料添加物
JP5970138B2 (ja) 新規なバクテリオファージ及びこれを含む抗菌組成物
JP6059827B2 (ja) 新規なバクテリオファージ及びこれを含む抗菌組成物
CN1265564A (zh) 给家禽服用活性微生物组合物的方法
JP6595761B2 (ja) バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
WO2007058027A1 (fr) Agent de contrôle d’une bacterie toxique contenant le bacillus thuringiensis
WO2007034627A1 (fr) Additif pour alimentation animale
EP1715755A1 (fr) Utilisation de bacteries vivantes permettant de promouvoir la croissance des animaux
JP5411405B2 (ja) 家畜・家禽用下痢抑制剤
WO2018155613A1 (fr) Composition pour la prévention et/ou le traitement d'une maladie de nécrose hépatopancréatique aiguë des crevettes comprenant une souche de bacillus amyloliquefaciens et/ou un produit traité de ladite souche
US20140037605A1 (en) Anticoccidial composition
WO2018155612A1 (fr) Composition pour la prévention et/ou le traitement d'une infection associée à la salmonelle comprenant une souche de bacillus amyloliquefaciens et/ou un produit traité de ladite souche
KR20180131948A (ko) 슈도모나스 익스트리모리엔탈리스 균주 kacc 81047bp 및 이를 포함하는 조성물
JP4903559B2 (ja) 家畜・家禽類又は魚介類の感染防除剤
JP6864293B2 (ja) 悪臭低減方法
WO1995004539A1 (fr) Adjuvant d'immunite et procede permettant de renforcer l'immunite d'un animal avec cet adjuvant
JP2007244372A (ja) バチルス・チューリンゲンシスを含む動物の腸内感染症予防・治療用の飼料添加剤
JP5970483B2 (ja) 胞子欠損Ｂ．テクサスポルス（Ｂ．ｔｅｘａｓｐｏｒｕｓ）細胞、及び効率的且つ費用対効果の高い不活性化のための方法、及びその使用
KR20140005573A (ko) 식물성 생균을 함유하는 가금류용 사료 조성물
RU2698189C1 (ru) Способ лечения сальмонеллеза рыб
Volodymyr et al. ECO-FRIENDLY BIOTECHNOLOGY FOR BIOGENIC NANOSELENIUM PRODUCTION AND ITS USE IN COMBINATION WITH PROBIOTICS IN POULTRY FEEDING: INNOVATIVE FEEDING CONCEPTS
JP5075369B2 (ja) 動物用飼料添加剤
RU2021126016A (ru) Композиции, содержащие бактерии, продуцирующие бациллен, или его препараты

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18758065

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18758065

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载